Co-Authors
This is a "connection" page, showing publications co-authored by ELIZABETH ANN MITTENDORF and HAVEN REBECCA GARBER.
Connection Strength
0.907
-
Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer. Oncotarget. 2024 Mar 19; 15:238-247.
Score: 0.237
-
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res. 2021 10 01; 27(19):5365-5375.
Score: 0.200
-
Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes. Clin Cancer Res. 2019 04 15; 25(8):2610-2620.
Score: 0.166
-
Adoptive T-cell therapy for Leukemia. Mol Cell Ther. 2014; 2:25.
Score: 0.122
-
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2023 Jun; 199(3):457-469.
Score: 0.056
-
Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation. Clin Cancer Res. 2022 09 01; 28(17):3669-3676.
Score: 0.053
-
Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma. Clin Cancer Res. 2018 07 15; 24(14):3386-3396.
Score: 0.039
-
Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia. 2017 01; 31(1):234-237.
Score: 0.035